Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.

被引：0
|
作者：
Vassilev, Zdravko
Fan, Xiaozhou
Ostojic, Helene
Xu, Julie
Barzi, Afsaneh
机构：
[1] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[2] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
64
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [21] FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Steffens, Claus-Christoph
    Brugger, Wolfram
    Hapke, Gunnar
    Illerhaus, Gerald
    Bluemner, Ernst
    Bokemeyer, Carsten
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [22] Upfront FOLFOXIRI plus bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer
    Stein, Alexander
    Atanackovic, Djordje
    Hildebrandt, Bert
    Stuebs, Patrick
    Brugger, Wolfram
    Hapke, Gunnar
    Steffens, Claus-Christoph
    Illerhaus, Gerald
    Bluemner, Ernst
    Stoehlmacher, Jan
    Bokemeyer, Carsten
    BRITISH JOURNAL OF CANCER, 2015, 113 (06) : 872 - 877
  • [23] Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line Therapy in Metastatic Colorectal Cancer?
    Nipp, Ryan D.
    Ryan, David P.
    ONCOLOGIST, 2015, 20 (03): : 236 - 238
  • [24] FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
    Loupakis, F.
    Cremolini, C.
    Salvatore, L.
    Masi, G.
    Sensi, E.
    Schirripa, M.
    Michelucci, A.
    Pfanner, E.
    Brunetti, I.
    Lupi, C.
    Antoniotti, C.
    Bergamo, F.
    Lonardi, S.
    Zagonel, V.
    Simi, P.
    Fontanini, G.
    Falcone, A.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) : 57 - 63
  • [25] Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)
    Adamo, Vincenzo
    Festa, Vincenzo
    Restuccia, Eleonora
    Chiofalo, Giuseppe
    Maisano, Carmelo
    Picciotto, Maria
    Alafaci, Elisabetta
    Tortora, Giampaolo
    ANNALS OF ONCOLOGY, 2007, 18 : 16 - 17
  • [26] Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
    Cremolini, Chiara
    Antoniotti, Carlotta
    Stein, Alexander
    Bendell, Johanna
    Gruenberger, Thomas
    Rossini, Daniele
    Masi, Gianluca
    Ongaro, Elena
    Hurwitz, Herbert
    Falcone, Alfredo
    Schmoll, Hans-Joachim
    Di Maio, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28) : 3314 - 3324
  • [27] EXPLORATORY ANALYSIS OF CIRCULATING PRO- AND ANTI-ANGIOGENIC FACTORS IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS, TREATED WITH GONO-FOLFOXIRI PLUS BEVACIZUMAB (BV)
    Cremolini, C.
    Loupakis, F.
    Salvatore, L.
    Fioravanti, A.
    Schirripa, M.
    Orlandi, P.
    Masi, G.
    Di Desidero, T.
    Fomaro, L.
    Canu, B.
    Baldi, G.
    Stasi, I
    Danesi, R.
    Bocci, G.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 40 - 40
  • [28] Treatment with bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Ocvirk, Janja
    Rebersek, Martina
    Boc, Marko
    Motara, Maja Ebert
    Mesti, Tanja
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] FOLFOXIRI plus bevacizumab (bev) as upfront treatment for metastatic colorectal cancer (mCRC) patients (pts) with initially unresectable liver-limited disease (LLD)
    Casagrande, M.
    Cremolini, C.
    Zucchelli, G.
    Bergamo, F.
    Ferrari, L.
    Pietrantonio, F.
    Lonardi, S.
    Loupakis, F.
    Masi, G.
    Pella, N.
    Intini, R.
    Salvatore, L.
    Tomasello, G.
    Pagani, F.
    Pellino, A.
    Dell'Aquila, E.
    Ginocchi, L.
    Milione, M.
    Fea, E.
    Pellegrinelli, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer: A retrospective analysis.
    Prenen, H.
    Geva, R.
    Piessevaux, H.
    Tejpar, S.
    Verslype, C.
    Vannoote, J.
    Mortier, L.
    Van Cutsem, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345